ad image

Preclinical CRO

1 / 1
State-of-the-Art, Multi-Modality Bioanalysis in Brisbane
Bioassays

State-of-the-Art, Multi-Modality Bioanalysis in Brisbane

Resolian

PAO-11-24-RTM-04Nov 12, 2024
Development Strategies for Overcoming Commercialization Challenges
Commercialization

Development Strategies for Overcoming Commercialization Challenges

Matthias Lucke, Ph.D.

Coriolis Pharma

PAO-09-24-CL-10Sep 17, 2024
Recombinant Antibody Technology is Crucial to Past and Future Success in Biopharma
Recombinant Antibody

Recombinant Antibody Technology is Crucial to Past and Future Success in Biopharma

Suranjana Sen, Ph.D.

Sino Biological

PAO-01-24-CL-4Jan 24, 2024
Innovations in Baculovirus–Insect Cell Expression Systems
Insect Cell Expression

Innovations in Baculovirus–Insect Cell Expression Systems

Amy Sheng, Ph.D.; Yingmin Zhu, Ph.D.; Xuejiao Zhang, Ph.D.

Sino Biological

PAO-09-23-CL-01Aug 31, 2023
Transforming Drug Development with Frictionless Access to Real-Time Preclinical Data
Preclinical Data

Transforming Drug Development with Frictionless Access to Real-Time Preclinical Data

Mark Mintz; Kristen M. Eisenhauer

Charles River Laboratories

PAO-05-23-CL-03May 05, 2023
Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos
Gene Tools

Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos

David Alvaro, Ph.D.; Jon Moulton, Ph.D.

Pharma's Almanac

PAO-01-23-CL-05Feb 01, 2023
Accelerated and Cost-Effective Antibody Design Using Artificial Intelligence
Artificial Intelligence in Antibody Design

Accelerated and Cost-Effective Antibody Design Using Artificial Intelligence

Sumana Sundaramurthy, Ph.D.

Sino Biological

PAO-11-022-CL-15Jan 10, 2023
Integrating Experimental Data and Artificial Intelligence to Accelerate Drug Discovery
Computational Drug Design

Integrating Experimental Data and Artificial Intelligence to Accelerate Drug Discovery

Ronald Dorenbos, Ph.D.; Guido Lanza

Charles River Laboratories

PAO-11-022-CL-11-180Dec 07, 2022
Optimized Multispecific Antibody Design, Development, and Manufacturing
Multispecific Antibodies

Optimized Multispecific Antibody Design, Development, and Manufacturing

Sino Biological

PAO-08-022-CL-04Aug 22, 2022
Taking a Customer-Focused Approach to Custom Antibody Development and Manufacturing
Recombinant Antibodies

Taking a Customer-Focused Approach to Custom Antibody Development and Manufacturing

Rob Burgess, Ph.D.; Amy Sheng, Ph.D.; Lilith Elmore

Sino Biological

PAO-04-022-CL-01Apr 07, 2022
Accurately Recapitulating Environmental Niches in In Vitro Models of the Intestine
Tissue Models

Accurately Recapitulating Environmental Niches in In Vitro Models of the Intestine

Liz Boazak, Ph.D.

Altis Biosystems

PAO-03-21-CL-01Mar 11, 2021
Developing a Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity
Tissue Models

Developing a Robust In Vitro Intestinal Model for Preclinical Candidate Screening of GI Toxicity

Ron Laethem, Ph.D.

Altis Biosystems

PAO-02-21-CL-04Feb 18, 2021
Recapitulating the Multifaceted Inflammatory Environment of the Intestine In Vitro
Tissue Models

Recapitulating the Multifaceted Inflammatory Environment of the Intestine In Vitro

Bailey Zwarycz, Ph.D

Altis Biosystems

PAO-02-21-CL-01Feb 04, 2021
Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells
Preclinical

Increasing the Efficiency of Drug Development with Preclinical Testing Using Human Intestinal Stem Cells

Ron Laethem, Ph.D.

Altis Biosystems

PAO-11-20-CL-01Dec 09, 2020
A Research Partner With Proven Results
Drug Discovery

A Research Partner With Proven Results

Daniel Conlon

IRBM

PAP-Q1-2019-CL-038Mar 12, 2019
1 / 1